- PharmaCielo is the first and only Colombian cannabis company to
receive the internationally recognized ISO 9001:2015
certification
- ISO 9001 certification affirms the company's commitment to
producing the highest quality medicinal-grade cannabis oils and
derived products
TORONTO and RIONEGRO,
Colombia, March 19, 2019 /CNW/ - PharmaCielo
Ltd. ("PharmaCielo" or the "Company")
(TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of
medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S.,
is pleased to announce the Company has received the ISO 9001:2015
certification for its cultivation and extraction operations.
The ISO 9001 certification, awarded to PharmaCielo, covers the
production of vegetable materials for the propagation, flowering
and production of both psychoactive (THC) and non-psychoactive
(CBD) cannabis. It was achieved following a rigorous audit process
conducted at the Company's Colombian facilities by inspection and
certification company SGS.
"PharmaCielo and our people continue to be the trailblazers of
the Colombian cannabis industry, and we keep raising the bar. We
were Colombia's first licensed
producer, and first recipient of quota for propagation, among other
milestones of industry leadership. Now, we are the first and
only local cannabis producer to receive this coveted quality
assurance certification," said David
Attard, CEO at PharmaCielo. "Receiving and adhering to the
high-quality requirements of the ISO 9001 standard truly sets
PharmaCielo apart and further attests to our commitment to
production of the highest quality medicinal cannabis oils."
"The recognition provided is the result of the quality and high
operating standards our Colombian team brings to the nursery," said
Federico Cock-Correa, president of
PharmaCielo Colombia Holdings SAS. "Without the dedication of
our team, recognition of the quality and consistency of our
operations would not be possible."
ISO 9001 is the international standard that specifies
requirements for a quality management system (QMS).
Organizations use the standard to demonstrate their ability to
consistently provide products and services that meet customer and
regulatory requirements.
"As the global medicinal cannabis market continues to evolve,
and additional markets open for the use of medical cannabis and
derived products, companies that can assure customers, patients,
healthcare providers and regulators of the quality and consistency
of the product will rise to the top. As such, PharmaCielo is well
positioned to become the preferred global supplier of
medicinal-grade cannabis oil extracts," added Dr. Delon Human, Chief Medical and Innovation
Officer.
The ISO 9001:2015 certification is another layer in
PharmaCielo's commitment to high quality and high operational
standards. PharmaCielo's processing facilities have been designed
and operate to fulfill GMP (Good Manufacturing
Processes) standards, ensuring that products are consistently
high in quality and guarantee total traceability. Receipt of
GMP certification for the Research and Technology Centre (RTC), as
the centre of medicinal oil extraction processes, is expected in
coming months.
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered
in Canada, with a focus on ethical
and sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered
at its nursery and propagation centre located in Rionegro,
Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
For further information:
www.PharmaCielo.com
About the International Organization for Standardization
(ISO)
ISO is an independent, non-governmental international
organization with a membership of 164. Through
its members, it brings together experts to share knowledge and
develop voluntary, consensus-based, market relevant International
Standards that support innovation and provide solutions to global
challenges. With 786 technical committees and
subcommittees to take care of standards development, and more
than 135 employees at ISO's Central Secretariat in
Geneva, Switzerland.
About SGS
SGS is the world's leading inspection, verification, testing and
certification company. SGS is recognized as the global benchmark
for quality and integrity. With more than 97,000 employees, SGS
operates a network of over 2,600 offices and laboratories around
the world.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of words
such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements include statements with respect to an
increase in the global medicinal demand for CBD cannabis, the
timing of approval or the receipt at all of approval of the
additional 20 strain applications awaiting approval, the ability of
PharmaCielo to fulfill global demand for pure CBD medicinal
cannabis oil extracts, and the timing of the registration of the 10
strains with the national cultivar registry. Forward-looking
statements are based on assumptions, including with respect to
PharmaCielo's planned products, and the ability to execute its
business plan that management believes are reasonable in the
circumstances, but the actual results, performance or achievements
of PharmaCielo's business may be materially different from any
future results, performance or achievements expressed or implied by
any forward-looking statements. Forward-looking statements can be
affected by known and unknown risks, uncertainties and other
factors, including, but not limited to, the equity markets
generally, risks associated with early stage companies, risks
associated with the regulation of cannabis and cannabinoid
derivatives, failure to obtain necessary TSXV approval, competition
for PharmaCielo's planned products, risks associated with operating
in Colombia, and currency exchange
risk. Accordingly, readers should not place undue reliance on
forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE PharmaCielo